TREM2 loss-of-function variants impair microglial survival, clustering around amyloid plaques, and phagocytic clearance, creating a non-cell-autonomous amplification loop where dysfunctional microglia accelerate tau pathology. This hypothesis has the strongest human genetic support (R47H OR ~2-4 for AD risk) and active clinical validation through AL002c Phase II trials (TRAILBLAZER-ALZ2). The mechanism is druggable via agonism antibodies, with validated biomarker (sTREM2) for patient stratificat
Site-specific TREM2 cleavage fragments (N-terminal vs C-terminal ratios) serve as the primary readout for microglial priming state, with CHI3L1 (YKL-40) and neurogranin as confirmatory cascade markers that validate the temporal sequence of neuroinflammation. The mechanistic foundation centers on ADAM10/17-mediated TREM2 shedding as the proximal event that defines microglial transition from homeostatic surveillance to priming phase. This transition triggers downstream CHI3L1 expression and synapt
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
TREM2BiomarkerNeuroinflammation
Convergent signals
TREM2 recurs across 2 selected hypotheses with aligned directionality in biomarker, neuroinflammation.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
9/11
dimensions won
TREM2-Deficient Microglia as Drivers of
3/11
dimensions won
CSF TREM2 Fragment Ratio Integrated with
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.80
0.65
Evidence
0.88
0.35
Novelty
0.65
0.00
Feasibility
0.85
0.00
Impact
0.82
0.00
Druggability
0.90
0.70
Safety
0.72
0.85
Competition
0.68
0.72
Data
0.85
0.80
Reproducible
0.82
0.65
KG Connect
0.50
0.50
Score Breakdown
Dimension
TREM2-Deficient Microglia as D
CSF TREM2 Fragment Ratio Integ
Mechanistic
0.800
0.650
Evidence
0.880
0.350
Novelty
0.650
0.000
Feasibility
0.850
0.000
Impact
0.820
0.000
Druggability
0.900
0.700
Safety
0.720
0.850
Competition
0.680
0.720
Data
0.850
0.800
Reproducible
0.820
0.650
KG Connect
0.500
0.500
Evidence
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxic
No evidence citations yet
CSF TREM2 Fragment Ratio Integrated with Neuroinflammatory C
No evidence citations yet
Debate Excerpts
TREM2-Deficient Microglia as Drivers of Amyloid Pl
4 rounds · quality: 0.49
Theorist
# Theoretical Analysis: TREM2-Deficient Microglia in Alzheimer's Disease
## Key Molecular Mechanisms
**TREM2-DAP12 Signaling Axis**: TREM2 is a surface receptor on microglia containing an immunogl...
Skeptic
## Critical Evaluation: TREM2 Hypothesis and Theoretical Analysis
### Core Strength Acknowledged
The genetic evidence is legitimately strong by AD standards—R47H represents one of the few variants...
Domain Expert
## Practical & Translational Assessment: TREM2 Agonism in AD
### Druggability: Favorable but CNS Delivery Is Key Challenge
TREM2 is a cell-surface receptor with a well-defined extracellular immuno...
Synthesizer
{"hypothesis_title":"TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease","synthesis_summary":"The TREM2 R47H variant represents one of the most robustly replicate...
CSF TREM2 Fragment Ratio Integrated with Neuroinfl
4 rounds · quality: 0.75
Theorist
# Biomarker Hypotheses for Detecting Microglial Priming States
---
## Hypothesis 1: TSPO PET Kinetic Modeling for Priming State Discrimination
**Title:** Distinguishing primed from dystrophic micro...
Skeptic
# Critical Evaluation of Microglial Priming Biomarker Hypotheses
## Hypothesis 1: TSPO PET Kinetic Modeling
### Weak Links
**Specificity Crisis.** TSPO is expressed on microglia, astrocytes, endoth...
Domain Expert
# Feasibility Assessment: Microglial Priming Biomarkers
## Executive Summary
The debate identified a fundamental translational gap: even validated microglial targets remain therapeutically inaccessi...